Ferroptosis: the emerging player in remodeling triple-negative breast cancer
Frontiers in Immunology · 20.10.2023 · 14
DOI: 10.3389/fimmu.2023.1284057 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Immunology, online erschienen am 20.10.2023. Verfasst von Jie Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thyroid and Breast Surgery, Shenzhen Qianhai Shekou Free Trade Zone Hospital, Shenzhen, China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Ferroptosis. Die Arbeit wurde bisher 61-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC) is a highly heterogeneous breast tumor type that is highly malignant, invasive, and highly recurrent. Ferroptosis is a unique mode of programmed cell death (PCD) at the morphological, physiological, and molecular levels, mainly characterized by cell death induced by iron-dependent accumulation of lipid peroxides, which plays a substantial role in a variety of diseases, including tumors and inflammatory diseases. TNBC cells have been reported to display a peculiar equilibrium metabolic profile of iron and glutathione, which may increase the sensitivity of TNBC to ferroptosis. TNBC possesses a higher sensitivity to ferroptosis than other breast cancer types. Ferroptosis also occurred between immune cells and tumor cells, suggesting that regulating ferroptosis may remodel TNBC by modulating the immune response. Many ferroptosis-related genes or molecules have characteristic expression patterns and are expected to be diagnostic targets for TNBC. Besides, therapeutic strategies based on ferroptosis, including the isolation and extraction of natural drugs and the use of ferroptosis inducers, are urgent for TNBC personalized treatment. Thus, this review will explore the contribution of ferroptosis in TNBC progression, diagnosis, and treatment, to provide novel perspectives and therapeutic strategies for TNBC management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thyroid and Breast Surgery, Shenzhen Qianhai Shekou Free Trade Zone Hospital, Shenzhen, China.
- Department of Nephrology, Renmin Hospital of Wuhan University, Wuhan, China.
- Department of Plastic Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.
- Department of Breast Surgery, Yueyang Central Hospital, Yueyang, Hunan, China.
Zitieren
APA
Li, J., He, D., Li, S., Xiao, J., & Zhu, Z. (2023). Ferroptosis: the emerging player in remodeling triple-negative breast cancer. Frontiers in Immunology, 14. https://doi.org/10.3389/fimmu.2023.1284057
Vancouver
Li J, He D, Li S, Xiao J, Zhu Z. Ferroptosis: the emerging player in remodeling triple-negative breast cancer. Frontiers in Immunology. 2023;14. doi:10.3389/fimmu.2023.1284057
BibTeX
@article{Li2023,
author = {Li, Jie and He, Dejiao and Li, Sicheng and Xiao, Jun and Zhu, Zhanyong},
title = {Ferroptosis: the emerging player in remodeling triple-negative breast cancer},
journal = {Frontiers in Immunology},
year = {2023},
volume = {14},
doi = {10.3389/fimmu.2023.1284057}
}
EUVIMED